---
title: "Blueprint Medicines Q4 Loss Narrows, Revenue Rises"
date: "2025-02-13 21:24:32"
summary: "Blueprint Medicines reported a Q4 net loss Thursday of $0.79 per diluted share, narrowing from a loss of $1.82 a year earlier. Analysts polled by FactSet expected a loss of $0.67. Revenue for the quarter ended Dec. 31, 2024, was $146.4 million, up from $72 million a year earlier. Analysts..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Blueprint Medicines reported a Q4 net loss Thursday of $0.79 per diluted share, narrowing from a loss of $1.82 a year earlier.

Analysts polled by FactSet expected a loss of $0.67.

Revenue for the quarter ended Dec. 31,Â 2024, was $146.4 million, up from $72 million a year earlier.

Analysts surveyed by FactSet expected $146 million.

The company's shares were down nearly 9% in recent Thursday premarket activity.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250213:A3316684:0/)
